FOXO4-DRI is a synthetic peptide designed to make senescent cells, the worn-out cells that build up with age, switch on their own self-destruct programme. It works in the lab by blocking a protein partnership between FOXO4 and p53 that helps those cells survive. So far, all the published research comes from cell cultures and mice, not people.
FOXO4-DRI has become one of the most talked-about compounds in ageing research since a 2017 paper in the journal Cell. A lot of what you read online makes it sound like a proven “anti-ageing peptide”. This plain-English guide from Peptides UK explains what it actually is, how researchers think it works, what the studies found, and where the gaps are. For laboratory research use only.
What is FOXO4-DRI in simple terms?
To understand FOXO4-DRI, it helps to know what senescent cells are. Normally, a damaged cell either repairs itself or is cleared away. Some cells do neither. They stop dividing but stay alive, and they release a mix of signalling molecules that can disturb the tissue around them. Scientists call these senescent cells, and they tend to build up as animals get older.
Inside many senescent cells, a protein called FOXO4 holds on to another protein called p53. p53 is often described as a guardian of the cell because it can trigger apoptosis, the tidy, programmed form of cell death. While FOXO4 keeps p53 tied up in the nucleus, the senescent cell avoids that self-destruct signal.
FOXO4-DRI is a short peptide based on part of the FOXO4 protein. It acts as a decoy: it competes for p53, breaks up the FOXO4 and p53 pairing, and lets p53 leave the nucleus. In senescent cells, that change was linked to the cells dying by apoptosis. Compounds that selectively remove senescent cells like this are known as senolytics.
What does “DRI” mean?
DRI stands for D-retro-inverso. Most proteins in nature are made from L-amino acids. A D-retro-inverso peptide uses the mirror-image D-amino acids and runs the sequence backwards. The result keeps a broadly similar shape to the original stretch of FOXO4, but enzymes that normally chop up peptides struggle to recognise it, so it lasts longer in experiments. Structural work has also shown that a cationic cell-permeability section of the peptide helps it get into cells and contributes to binding p53 (Bourgeois et al., 2025, PubMed 40593617).
FOXO4-DRI at a glance
| Property | Detail |
|---|---|
| Type | Synthetic D-retro-inverso peptide based on part of the FOXO4 protein |
| Main target | The interaction between FOXO4 and p53 in senescent cells |
| Research category | Senolytic (selective removal of senescent cells) |
| First described | Baar et al., Cell, 2017 |
| Evidence base | Cell culture and mouse studies only |
| UK status | Not a licensed medicine; laboratory research use only |
What does the FOXO4-DRI research show?
The published work is still small and entirely pre-clinical. Here are the key studies in plain English.
The original 2017 study in Cell
A team led by Peter de Keizer at Erasmus University Medical Center in Rotterdam identified FOXO4 as a key reason senescent cells stay alive. They designed the FOXO4 peptide, showed that it pushed p53 out of the nucleus and caused apoptosis in senescent cells, and then tested it in mice. In both fast-ageing mice and naturally aged mice, they reported improvements in fitness and fur density (Baar et al., 2017, PubMed 28340339). This is the paper most other research builds on.
How the peptide grips p53
In 2025, researchers in Graz and Utrecht used NMR spectroscopy to look at how FOXO4-DRI binds p53. They found that the peptide and a flexible region of p53 come together to form a short-lived, partly folded complex, and that a chemical tag on p53 (phosphorylation) made the binding stronger (PubMed 40593617). It is worth knowing that some of the authors disclosed patents and shares in a company developing related compounds, which the paper states openly.
Ageing studies in specific tissues
- Cartilage cells: a University of Pittsburgh study found FOXO4-DRI removed more than half of the cells in heavily expanded human cartilage cell cultures and lowered senescence markers, while barely affecting less-expanded cells. It did not improve cartilage formation, and the authors said more work was needed (Huang et al., 2021, PubMed 33996787).
- Testes in aged mice: two studies from Sun Yat-sen University reported that FOXO4-DRI cleared senescent Leydig cells in cell models and, in naturally aged mice, was linked to better testosterone output and sperm quality (Zhang et al., 2020, PubMed 31959736; Li et al., 2024, PubMed 39025385).
- Blood vessels: a 2026 study from Wenzhou Medical University reported that FOXO4-DRI reduced signs of ageing in the aorta of aged and fast-ageing mice, acting through the p53, BCL-2 and caspase-3 pathway (Hu et al., 2026, PubMed 41625068).
Myths vs facts about FOXO4-DRI
- Myth: “FOXO4-DRI reverses ageing.” Fact: some markers of ageing improved in mice under controlled conditions. That is not the same as reversing ageing, and no human results have been published.
- Myth: “It only ever kills bad cells.” Fact: studies report that it is selective for senescent cells, but selectivity is measured in specific lab models and is not absolute.
- Myth: “The science is settled.” Fact: the field is young. Most of the evidence comes from a handful of groups, and longer, independent studies are still needed.
Why the evidence has limits
Mouse studies are a valuable starting point, but results in mice often do not carry over to people. Many of the FOXO4-DRI studies use small numbers of animals and very specific models of ageing. A paper about FOXO4-DRI as a substance also tells you nothing about whether a particular batch sold online is the right molecule at the stated purity. That is why batch paperwork matters so much for research peptides.
Is FOXO4-DRI legal in the UK?
FOXO4-DRI has no UK marketing authorisation, so it is not a medicine. Research peptides like it are supplied in the UK for laboratory research use only. Whether a product counts as a medicine depends on how it is presented and used, so labs should follow current guidance from the MHRA and their own institutional rules. This article is not legal advice.
Buying FOXO4-DRI for laboratory research in the UK
If your lab is sourcing FOXO4-DRI, a few simple checks go a long way:
- Ask for a batch-matched Certificate of Analysis (COA). Because FOXO4-DRI is built from D-amino acids, identity checks such as mass spectrometry matter as much as the purity figure. Our guide on how to read a COA explains what to look for.
- Check the format. Confirm the vial size and that it is a freeze-dried (lyophilised) powder that matches the label.
- Plan storage. Freeze-dried peptides keep best cold, dry and away from light. See our peptide storage guide.
- Compare suppliers on evidence. Our page on the best research peptides in the UK sets out what a trustworthy supplier should show you.
Peptides UK lists FOXO4-DRI for lab research in a 10mg vial, HPLC and COA Verified, with the COA available on request by emailing [email protected]. You can browse the rest of the range in our research peptide shop.
Frequently asked questions
What is FOXO4-DRI?
FOXO4-DRI is a lab-made peptide designed to block the contact between two proteins, FOXO4 and p53, inside senescent (worn-out, non-dividing) cells. In cell and mouse studies, breaking that contact caused senescent cells to self-destruct while leaving healthy cells largely alone.
What does DRI stand for in FOXO4-DRI?
DRI stands for D-retro-inverso. The peptide is built from D-amino acids, the mirror-image forms of the usual building blocks, arranged in reverse order. This keeps a similar overall shape to the original sequence but makes the peptide much harder for enzymes to break down in the lab.
Is FOXO4-DRI a senolytic?
Yes. Researchers describe FOXO4-DRI as a senolytic, meaning a compound studied for its ability to selectively remove senescent cells. It is a peptide senolytic, which makes it different from the small-molecule senolytics more often discussed in ageing research.
Has FOXO4-DRI been tested in humans?
No published, completed human clinical trials of FOXO4-DRI were found in PubMed when this guide was written. The evidence comes from cell cultures and mouse models, so nothing can be concluded about effects or safety in people.
Is FOXO4-DRI legal to buy in the UK?
FOXO4-DRI is not a licensed medicine in the UK. Like other research peptides, it is supplied for laboratory research use only. How a product is classed depends on how it is presented and used, so labs should check current MHRA guidance and their own institutional rules. This is not legal advice.
All Peptides UK products are for laboratory research use only. They are not medicines and are not for human or veterinary use. This article is for educational purposes and is not medical or legal advice.